English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
News
iCMLf Knowledge Centre - new eLearning tool for clinicians, molecular biologists and pathologists
iCMLf Knowledge Centre - new eLearning tool for clinicians, molecular biologists and pathologists
June 2018 - The iCMLf is delighted to announce the launch of the iCMLf Knowledge Centre, an interactive online resource providing educational content on CML. This new resource complements the other major online educational programs as part or our efforts to improve clinical practice and disease monitoring in CML worldwide through global education initiatives.
Obituary Tessa Holyoake
We are very sad to hear the news of the death of our friend and colleague Tessa Holyoake.
'Along with her many other achievements Tessa was an integral part of the iCMLf Advisory committee. She was also Co-Chair of our annual iCMLf/ESH John Goldman Meeting. She was always quick with advice and ideas. Even as her health was failing she continued to make critical contributions to the upcoming meeting. Tessa hosted iCMLf clinical preceptors since 2015. It is testament to her inspirational leadership and generosity that so many preceptors that visited Tessa in Glasgow became long term collaborators.
She will be sorely missed both personally and professionally'.
(Tim Hughes, Chairman of the iCMLf)
CML highlights from EHA 2017 - read an overview
July 2017 - Important CML news was among the scientific data presented at the 22nd Meeting of the European Association of Hematology (EHA) in Madrid. This included; data on the use of dasatinib in children and adolescents, new data comparing bosutinib with imatinib in frontline therapy and the 24-month results from the British Destiny Study.
We are delighted to provide you with summaries of this key CML information presented at the congress and to have two CML experts sharing their personal perspectives of the EHA highlights.
iCMLf website now features key CML publications from the Emerging Economic Regions
May 2017 - In order to better recognise the scientific achievements in the emerging economic countries the iCMLf has recently launched a new section of the website that features key CML publications from these regions. You will find interesting articles on CML that have been published in peer-reviewed journals in the Middle East, Africa, Asia and Latin America.
The page will be updated regularly with new publications from the emerging economic regions. We also rely on your help. If you have an interesting CML paper or article from your country to share, please email to info@cml-foundation.org and provide us with the details. We will be happy to review your suggestion.
You can access the new ERSAP Publications page here
iCMLf Diagnosis and Testing Program - Apply now for 2017 grants
April 2017 - The iCMLf Diagnosis and Testing Program offers seeding grants to hematology institutions in emerging economic regions. The aim of the program is to facilitate the diagnosis, testing and long-term disease monitoring of CML patients in emerging economic regions where it is either limited, or not currently available.
Over five years the iCMLf have awarded 42 grants to enable CML diagnostics to be expanded and enhanced at a local level. This gives both physicians and patients the knowledge to make meaningful decisions on treatment. In 2017 the Foundation will again offer 10 grants with funding of up to $10,000.
Applications will close on the 30th of June 2017. Proposals are welcome to melissa@cml-foundation.org or read more for further information on how to apply.
Rare Disease Day 2017
February 2017 - February 28th is Rare Disease Day! Today organizations supporting rare diseases and patients all over the world raise awareness for rare diseases aiming to improve access to treatment and care for 300 millions of people affected by rare diseases.
The outcomes for patients with CML have improved significantly over the past years thanks to new treatment options available, but there is still a lot to do to grant equal access to appropriate treatment and monitoring for patients around the world, especially in emerging economic regions– one of the core objectives of the iCMLf.
Learn more about rare disease here, courtesy of the Mesothelioma Cancer Alliance.
Make sure to get involved using #RareDiseaseDay
